🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)5mg doing nothing - should I ask to go up? Page 2

5mg doing nothing - should I ask to go up?

nick_newbie Mon, Apr 13, 2026 at 3:31 AM 10 replies 770 viewsPage 2 of 2
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Apr 13, 2026 at 4:46 PM#6
BenResearch_OR said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

This is where I part company with the consensus forming above. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

20 15fiona_VT, denise_HTX, raj_cambridge and 17 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Apr 13, 2026 at 10:01 PM#7

One concrete data point for the thread. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

Last edited: Apr 14, 2026 at 1:01 AM
19 14hank_denver, carlos_SATX, sophie_paris and 16 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Apr 14, 2026 at 3:15 AM#8
DanielChem_CHI said:
The "tirzepatide is simply better" summary irritates me.

Adding the part of the answer the thread has not reached. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

18 13adam_van, Dr.SurgeonPGH, rachel_ABQ and 15 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Apr 14, 2026 at 8:29 AM#9

Following on from quinn_sf — and this may be the naive question:

How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?

17 12julia.endo, JessicaM_2024, TomFromTexas and 14 others
Reply Quote Save Share Report
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Apr 15, 2026 at 9:37 AM#10

Closing the loop on my own question.

Reporting back after another eight months at the same dose. Still losing slowly, no new side effects, and no reason I can find to climb further.

47 22wanda_boise, NurseAsh_DET, BenResearch_OR and 44 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register